Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
Titel:
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
Auteur:
Weisel, Katja Mateos, Maria-Victoria Landgren, Ola Leleu, Xavier Quach, Hang Bennett, Lee Talpes, Mihaela Majer, Istvan Patel, Sachin Usmani, Saad Z.